Key Proteo Inc

Key Proteo Inc. is a privately held company headquartered in the United States. With five employees, Key Proteo focuses on revolutionizing the medical landscape through cutting-edge proteomic analysis. Their core mission is to democratize early detection of rare, treatable genetic disorders. Key Proteo specializes in developing novel methods for identifying extremely low abundance protein biomarkers, often undetectable through traditional screening methods. Their initial focus is on newborn screening, aiming to identify treatable genetic disorders in infancy, enabling timely intervention and potentially altering the disease trajectory. What sets Key Proteo apart is its commitment to accessible proteomic analysis. Their innovative technologies aim to make early detection of these disorders more widespread, benefiting a broader patient population. By focusing on early intervention, Key Proteo strives to significantly improve patient outcomes and alleviate suffering for families affected by rare genetic disorders. Visit Key Proteo online at keyproteo.com for more information.